What is the influence of genotype on the success of treatment for chronic hepatitis B? Commentary

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 3, Issue 11, 2006, Pages 620-621

  Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2B;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; GENETIC VARIABILITY; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; SCORING SYSTEM; SEROCONVERSION; SHORT SURVEY; TREATMENT OUTCOME;

EID: 33750471591     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep0628     Document Type: Short Survey

References (5)

1. Echevarria JM and Avellon A (2006) Hepatitis B virus genetic diversity. J Med Virol 78 (Suppl 1): S36-S42
2. +) chronic hepatitis than genotype C. Hepatology 36: 1425-1430
3. Erhardt A et al. (2005) Response to interferon alfa is hepatitis B virus genotype dependent: Genotype A is more sensitive to interferon than genotype D. Gut 54: 1009-1013
4. Lau GK et al. (2005) Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352: 2682-2695
5. Cooksley WG et al. (2003) Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10: 298-305